Mpi: First Patient Dosed In Phase 2 Study Of The Parp Inhibitor 2x121 For Breast Cancer | Latest News RSS feed

Mpi: First Patient Dosed In Phase 2 Study Of The Parp Inhibitor 2x121 For Breast Cancer - Latest News


MPI: First Patient dosed in Phase 2 Study of the PARP Inhibitor 2X-121 for Breast Cancer

"This Phase 2 study will enable us to rapidly evaluate the efficacy of our PARP inhibitor ... with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI`s DRP® tool ... read more

Myriad Genetics: Exciting Alzheimer's Treatment In the Pipeline

All patients in the U.S. phase III study ... PARP (poly-ADPribose polymerase) inhibitor, to treat patients with breast cancer or ovarian cancer associated with an inherited mutation in one of the ... read more

Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division

Chromosomal instability (CIN) is a common trait of cancer characterised by the continuous gain and ... 5% mannitol). Description of study design and materials and methods used for cell proliferation ... read more

Looking for another news?


AstraZeneca Full-Year and Q4 2018 Results

As we recently entered a new phase in our strategic ... more and more patients around the world." Financial summary - Product Sales increased by 4% in the year to $21,049m; new medicines generated ... read more


MPI: First Patient dosed in Phase 2 Study of the PARP Inhibitor 2X-121 for Breast Cancer

Hoersholm, Denmark, June 26, 2018 - Medical Prognosis Institute A/S (MPI ... dosing of the first patient in a Phase 2, clinical study to investigate the anti-tumor effect and tolerability of 2X-121 in ... read more

MPI - Strong LiPlaCis Treatment Results in DRP-Selected Breast Cancer Patients - Collaborative LiPlaCis Regulatory Meeting with DKMA

2018 -Medical Prognosis Institute (Nasdaq First North; MPI:ST) and Oncology Venture Sweden AB (OV.ST) ("OV" or "the Company") announce the third interim report from the ongoing LiPlaCis® Phase 2 study ... read more

First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer

(“OV”) and Medical Prognosis Institute A/S (MPI:ST) today announced dosing of the first patient in a Phase 2, open-label clinical trial to investigate the anti-tumor effect and tolerability of 2X-121 ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us